Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.51 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.51 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.51 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.51 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.51 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12505085 | 0.99 | TRPV1 (0.53) | TRPV1HDAC3HDAC1HDAC2HDAC4 | |
| SCHEMBL531059 | 0.87 | HPGD (0.61) | TRPV1HDAC3HDAC1HDAC2HDAC4 | |
| SCHEMBL20101172 | 0.81 | HDAC3 (0.46) | TRPV1HDAC3HDAC1HDAC2HDAC4 | |
| SCHEMBL20101139 | 0.81 | HDAC1 (0.47) | TRPV1HDAC3HDAC1HDAC2HDAC4 | |
| SCHEMBL21171734 | 0.80 | HDAC3 (0.44) | HDAC3HDAC1HDAC2HDAC4HDAC7 | |
| SCHEMBL20101171 | 0.80 | HDAC3 (0.45) | TRPV1HDAC3HDAC1HDAC2HDAC4 | |
| SCHEMBL5020897 | 0.80 | HDAC3 (0.61) | TRPV1HDAC3HDAC1HDAC2 | |
| SCHEMBL30445391 | 0.79 | EPHX2 (0.61) | TRPV1HDAC3HDAC1HDAC2HDAC4 | |
| SCHEMBL30444584 | 0.79 | EPHX2 (0.61) | TRPV1HDAC3HDAC1HDAC2HDAC4 | |
| SCHEMBL17955251 | 0.78 | HDAC3 (0.43) | TRPV1HDAC3HDAC1HDAC2HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9988627-B2 | Formats for organic compounds for use in RNA interference | NOVARTIS AG (CH) | 2018-06-05 | — | — | US | disclosed |
| US-20160304863-A1 | 3'END CAPS FOR RNAi AGENTS FOR USE IN RNA INTERFERENCE | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2016-10-20 | — | — | US | disclosed |
| US-20160244756-A1 | NOVEL FORMATS FOR ORGANIC COMPOUNDS FOR USE IN RNA INTERFERENCE | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2016-08-25 | — | — | US | disclosed |
| US-20160215288-A1 | ORGANIC COMPOUNDS TO TREAT HEPATITIS B VIRUS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2016-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304863-A1 | 3'END CAPS FOR RNAi AGENTS FOR USE IN RNA INTERFERENCE | RNGTT, NSUN2, NSUN3 | TRPV1 4491/4885HDAC3 1654/4885HDAC1 1903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.